? With backing from Novo Holdings and a drug from AstraZeneca, Aristea Therapeutics is unveiling a $15 million Series A that will kickstart Phase II studies of its lead program, RIST4721. James Mackay, who used to run AstraZeneca-acquired Ardea Biosciences, is the founder and CEO of the San Diego-based startup. He?s staying mum on details about Aristea?s pipeline of treatments for serious inflammatory diseases, preferring instead to highlight the combined expertise of his crew of ex-Ardea execs: John Montana, SVP of development; Sara McCutchan, regulatory affairs manager; and DeAnne Reid, director of operations. Tiba Aynechi and Ken Harrison
Novo helps birth startup advancing an AstraZeneca castoff with $15M; Japan’s Fuji Pharma wagers $50M on Alvotech’s biosimilars
